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Essentials: 
 A strong association between bleeding severity and FXIII activity level 
(FXIII:C) was shown. 
 The range 5-30 IU/dL of FXIII:C was associated with a high variability of 
bleeding severity. 
 The PROspective study confirmed the association between FXIII:C activity 
and bleeding severity. 
A FXIII:C of 15 IU/dl is a proposed target to start prophylaxis for prevention of major 
bleeding. 
 
ABSTRACT 
Background: Congenital factor XIII (FXIII) deficiency is a rare bleeding disorder 
associated with significant bleeding manifestations. The European Network of Rare 
Bleeding Disorders (EN-RBD) study, performed from 2007 to 2010, showed a strong 
association between bleeding severity and FXIII activity in plasma of patients with 
FXIII deficiency. Among these patients variable levels of FXIII activity, from 
undetectable to 30%, were associated with a wide range of bleeding severity. 
Objectives and patients: The present cross-sectional study, in the frame of the PRO-
RBDD project, a prospective cohort study, analyzed data of 64 patients with FXIII 
deficiency and different types of clinical and laboratory severity. Results: The results 
of this analysis confirmed that FXIII coagulant activity in plasma is well associated 
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with clinical severity of patients. In addition, 15 IU/dl of FXIII activity was identified to 
be the level under which the probability of spontaneous major bleeding sharply 
increases (from 50% for levels of 15 IU/dL to more than 90% for levels of 5 IU/dL or 
lower). Conclusion: the PRO-RBDD study suggests a FXIII coagulant activity level of 
15 IU/dL as a target to start prophylaxis in order to prevent major bleedings, such as 
central nervous system or gastrointestinal tract hemorrhages. 
 
KEYWORDS: Factor XIII, Factor XIII deficiency, Haemorrhage, Phenotype, 
Prophylaxis 
 
INTRODUCTION 
Coagulation factor XIII (FXIII) is a plasma protransglutaminase heterotetramer 
composed of two FXIII-A and two FXIII-B subunits, which following activation by 
thrombin and Ca2+ acts in the last step of the coagulation cascade [1]. The major 
function of FXIII is to stabilize blood clots by cross-linking fibrin chains and 
incorporating antifibrinolytic proteins during hemostasis [2]. This makes the blood 
clot highly resistant to premature degradation by fibrinolytic proteins [3]. FXIII is 
capable of cross-linking a wide range of proteins and is involved in a number of 
processes beyond coagulation, including wound healing and tissue repair [4], 
fibroblast migration and proliferation, phagocytosis, and angiogenesis of the 
endothelial barrier [5-8]. FXIII is also necessary for the maintenance of pregnancy [9-
11]. 
Congenital FXIII deficiency is transmitted as an autosomal recessive trait, and is 
caused by defects in the F13A1 (OMIM #613225) and the F13B genes (OMIM 
#613235). Since its first description in 1960 more than 500 cases of FXIII deficiency 
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have been identified worldwide, and most of them concern the deficiency of the FXIII 
A subunit [6,12]. The prevalence of FXIII-A deficiency has been estimated at one 
case in 2–3 million, however this data may change in different region of the world 
[13,14]. The clinical symptoms of FXIII deficiency include delayed wound healing, 
recurrent spontaneous miscarriage, bleeding of soft and subcutaneous tissue and 
life-threatening spontaneous central nervous system bleeding, which is the primary 
cause of death in affected patients [14-19]. In cases of severe FXIII deficiency, early 
manifestation as umbilical cord bleeding occurs frequently during the neonatal period 
[14]. 
 
Despite the severity of FXIII deficiency, the clinical and phenotypic characteristics 
remain poorly characterized. In 2012, the European Network of Rare Bleeding 
Disorders (EN-RBD) analyzed data of 489 patients with rare bleeding disorders 
(RBDs) and reported the results on the association between clotting plasma levels 
and bleeding severity for each coagulation factor deficiency [20]. This same report 
showed a strong association between FXIII activity levels and clinical bleeding 
severity, with a heterogeneous bleeding tendency, in patients with FXIII coagulant 
activity level (FXIII:C) ranging from undetectable to 30 IU/dL. Patients with FXIII:C 
≥30 IU/dL remained almost asymptomatic [20]. Surprisingly, patients with FXIII 
activity levels between 5 to 30 IU/dL, in addition to spontaneous minor (grade II) or 
post-traumatic (grade I) bleeding, showed also spontaneous major bleeding (grade 
III) such as umbilical cord bleeding [20]. Therefore, a definition of minimum FXIII 
coagulant activity level to prevent spontaneous major bleeding is desirable to better 
guide therapeutic decision.  
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Retrospective analyses, clinical trials and, more recently, prospective analyses have 
shown that prophylactic treatment with FXIII concentrate can produce sufficient FXIII 
activity levels for normal hemostasis [21-24].  
 
With this as background, a cross-sectional study of FXIII-deficient patients was 
performed in the frame of the Prospective Rare Bleeding Disorders Database (PRO-
RBDD),  with the goal of confirming the data obtained by the EN-RBD in a wider and 
different group of patients, and establishing the minimum FXIII activity level to 
prevent major spontaneous bleedings. This was an attempt to support clinicians in 
their decision on which patient should start a prophylactic replacement therapy. 
 
This study was conducted in cooperation with the EUropean HAemophilia NETwork 
with the support of the European Commission Health Programme through the 
Executive Agency for Health and Consumers (EAHC) [25]. 
 
METHODS 
Data collection 
The PRO-RBDD project was designed to collect data on demographics, laboratory 
phenotypes, genotypes, clinical manifestations, surgery, treatment types and the 
long-term safety and efficacy of treatment in patients affected with RBDs worldwide. 
A dedicated group consisting of specialists in the field and clinical epidemiologists 
have worked with informational technology team to implement the previous EN-RBD 
interactive web-based database to include new variables and to allow for data 
collection at sequential checkpoints. Ethical approval, in accordance with national 
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and international ethical standards, was obtained from the ethical review board of the 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. All 
enrolled patients or their parents provided written informed consent.  
Data collection began in February 2013 and was designed to include two different 
sets of data: 1) a retrospective data set to be collected at baseline (demographic 
data and data on the history of patient from birth to the time of enrolment); 2) a 
prospective data set to be collected at six follow-ups (at least one every six months, 
over three years). For the purposes of the current study, the analysis focused on the 
retrospective data set of patients with FXIII deficiency (baseline data).  
The previous classification proposed by the EN-RBD was used to classify baseline 
data to have a standard definition of laboratory phenotype and bleeding severity [20]. 
The laboratory phenotype severity was classified into severe (undetectable FXIII:C in 
plasma), moderate (FXIII:C from lower detection limit to 29 IU/dL) and mild (FXIII:C 
30 IU/dL to normal levels) FXIII deficiency. The bleeding severity was classified into 
four categories: asymptomatic (no documented bleeding episodes), grade I bleeding 
(bleeding after trauma or drug-induced), grade II bleeding (spontaneous minor 
bleeding – mucocutaneous), and grade III bleeding (spontaneous major bleeding – 
umbilical, gastrointestinal and central nervous system bleeding, hemarthrosis and 
hematoma).  To better understand the association between clinical severity of the 
patients and laboratory phenotype, in addition to bleeding severity, data on (1) age at 
first bleeding, (2) reason for diagnosis or age at diagnosis and (3) type of treatment 
were also retrieved and analyzed.  
Data were collected from 17 centers of 12 countries, including the Czech Republic, 
Germany (2), Greece, France, Italy, The Netherlands, Pakistan, Serbia, Switzerland, 
Turkey (2), USA (2) and the United Kingdom (3). According to World Health 
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Organization Global Health Observatory data [26], all countries were classified as 
upper middle or high income countries except one, defined as a lower middle income 
country. 
 
Laboratory analysis 
All the 64 patients included in this study were tested locally for FXIII:C. However, 
partners had the possibility to send centrally plasma for confirmation of diagnosis, 
free of charge (central laboratory: Division of Clinical Laboratory Science, University 
of Debrecen, Hungary). This service was offered with the aim of using an alternative 
laboratory method with a limit of detection lower than that obtained by local methods. 
This service was not utilized by all centers probably due to problems in finding dry 
ice or in shipping samples. 
 
For 29 of the 64 patients included in the study (of whom 22 had a severe laboratory 
phenotype), the baseline FXIII:C values of the local laboratory were confirmed by the 
central laboratory. After a high correlation between the two measurements was 
demonstrated, the central lab values were used for our analyses. For all the other 
patients (n=35, of whom 9 with a moderate and 17 with a mild laboratory phenotype) 
the FXIII:C values of the local laboratory were used.  
 
FXIII:C was measured using ammonia release assay, as previously described [27]. 
The concentration levels of FXIII-A2B2 (plasma) [28], FXIII-A (plasma and platelets) 
[29] and FXIII-B (plasma) [30] subunits were also measured using ELISA assays. 
Plasma samples were collected at least 21 days after the last treatment (if any).  
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Statistical analysis 
Data are presented as medians and interquartile ranges (IQR) for continuous 
variables and as counts and percentages for categorical variables. The Pearson’s 
test was used to check the correlation between FXIII:C values of samples tested 
both locally and at the central laboratory. Chi-square test was used to test 
differences between categories of laboratory phenotype severity and bleeding 
severity (from 0 = asymptomatic to 3 = grade III bleeding). Goodman and Kruskal’s 
gamma was used to determine the intensity and direction of associations between 
ordinal variables. A regression model taking family dependence into account was 
also performed (three patients had two relatives included in the database, and three 
patients, one). Linear regression analysis was used to determine the association 
between FXIII:C (dependent variable) and the age at first bleeding or at diagnosis 
(continuous variable), with adjustment for sex and country in which the patient was 
diagnosed. Differences between the median age at first bleeding or at diagnosis 
according to the three categories of laboratory phenotype severity of FXIII deficiency 
were assessed using the Kruskal-Wallis test. To find out the level of FXIII:C that 
better discriminates patients with or without grade III bleeding, a multivariable logistic 
regression model was built in which grade III bleeding was the outcome and FXIII:C 
(kept continuous) was the predictor, adjusting for age and sex. Values of FXIII:C 
below the lowest level of detection in the FXIII:C assay were represented as half of 
the lowest detection limit (i.e. in case of samples analyzed only locally, where the 
lowest detection limit was 5 IU/dL a value of 2.5 IU/dL was used; in the samples 
analyzed at the central laboratory where the lowest detection limit was 1 IU/dL a 
value of 0.5 IU/dL was used). In the logistic model, restricted cubic splines with three 
knots were used to search for possible non-linear relationships between FXIII:C and 
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the outcome, expressed as log odds. Following the relationship between log odds 
and probability (probability = exp (log odds) / [1 + exp (log odds)], a probability curve 
was obtained, which represents the predicted probability of grade III bleeding 
according to different levels of FXIII:C. Receiver operating characteristic (ROC) 
curve was used to assess what FXIII:C level better discriminated patients with or 
without grade III bleeding. Sensitivity and specificity for different FXIII:C levels were 
calculated. The area under the ROC curve (AUC) with 95% CI was used as estimate 
of the predictive capability of the logistic model. An internal validation of the 
predictive model was performed with 1000 bootstrap replicates in order to correct for 
optimism. All p-values are two-sided and correspond to a significance level of <0.05. 
All analyses were performed using the statistical software R, release 3.2.3 (R 
Foundation for Statistical Computing, Vienna, Austria).  
 
RESULTS 
For the 29 samples tested both locally and at the central laboratory, a very high 
correlation between the two FXIII:C values was observed (ρ=0.97, p<0.001). 
Baseline characteristics of the 64 patients with FXIII deficiency are shown in Table 1. 
Thirty-five patients (55%) had grade III bleeding, which mostly occurred in those 
patients with severe FXIII deficiency, eight (12%) had grade II bleeding, ten (16%) 
had grade I bleeding. Five patients (8%, all with mild FXIII deficiency) bled only 
during pregnancy, and 6 patients (9%, all with mild deficiency), remained 
asymptomatic at the time of their inclusion into the study (median age of 43 years). 
Seven out of 64 patients had been previously registered in the EN-RBD database. 
The results showed below, that refer to the entire PRO-RBDD population, did not 
differ when the analyses were performed excluding these seven patients. 
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Association between clinical severity and laboratory phenotype severity 
Bleeding severity  
Grade III bleeding episodes were observed in 90% of patients with undetectable 
FXIII:C in plasma (Table 1). No patient with FXIII:C <30 IU/dL remained 
asymptomatic at the time of inclusion in the study. Grade III bleeding episodes were 
surprisingly observed also in 46% of patients with FXIII:C between the lower 
detection limit and 29 IU/dL. No symptoms were observed in 43% of patients with 
mild FXIII deficiency. An association between laboratory phenotype and bleeding 
severity was confirmed by Chi-Square test and Goodman and Kruskal’s gamma (2 
= 46, p <0.0001; G = −0.86, 95% CI: −0.97 to −0.74).  
 
Age at first bleeding 
The age at first bleeding was recorded in 54 patients. After adjustment for sex and 
center of diagnosis, linear regression analysis showed a positive association 
between the age at first bleeding and FXIII:C (β = 0.81 [95% CI: 0.41 to 1.19] for 
every 1-year increase). The linear regression model taking family dependence into 
account led to only trivial changes in the 95% CIs. Similarly, the age at first bleeding 
varied according to laboratory phenotype severity (Fig. 1A, p <0.0001), and most of 
the patients with undetectable FXIII:C presented bleeding symptoms at neonatal 
age. 
 
Reason for diagnosis or age at diagnosis 
The age at diagnosis was recorded in all patients. Almost all patients with FXIII:C 
<30 IU/dL were diagnosed due to bleeding episodes, while patients with FXIII:C 
≥30IU/dL were diagnosed following either a bleeding episode or screening test (as a 
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relative of a patient). After adjustment for sex and center of diagnosis, linear 
regression analysis showed a positive association between the age at diagnosis and 
FXIII:C (β = 0.57 [95% CI: 0.27 to 0.88] for every 1-year increase). The linear 
regression model taking into account the family dependence led to only trivial 
changes in the 95% CIs. Age at diagnosis differed according to laboratory phenotype 
severity (Fig. 1B, p <0.0001). In patients with undetectable FXIII:C the median age 
(IQR) at first bleeding was 0 years [0 to 1], lower than that at diagnosis, (5 years [2.5 
to 9]). 
 
Type of treatment 
Data on type of treatment was retrieved for all 64 FXIII-deficient patients; 19 out of 
31 (61%) patients with undetectable FXIII:C and seven out of 13 (54%) patients with 
FXIII:C between lower limit of detection and 29 IU/dL received prophylactic 
treatment. Prophylaxis was only provided to 57% of the patients with grade III 
bleeding episodes (20 out of 35). The 15 patients with grade III bleeding not 
receiving prophylaxis were from Pakistan (9), Turkey (3), Germany (2) and Italy (1). 
 
Minimal FXIII coagulant activity to prevent grade III bleeding 
A linear increase in the log-odds of grade III bleeding with decreasing levels of FXIII 
activity was observed (Fig. 2A; p = 0.52 for the non-linear component). The 
probability curve (Fig. 2B) shows that the predicted probability of grade III bleeding 
steeply increases for FXIII coagulant activity levels <20 IU/dL, with a probability of 
about 50% for levels of 15 IU/dL and >90% for levels of 5 IU/dL or lower. Those 
patients suffering from grade III bleeding all had FXIII activity levels ≤16 IU/dL (Fig. 
3). The six patients with detectable FXIII:C deficiency and grade III bleeding (Table 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
1) had FXIII activity levels between 5 and 16 IU/dL. In order to widening the 
description of this particular group of patients, additional information about 
genotyping, FXIII:C tests and any possible treatment, if any, were also extrapolated 
from the PRO-RBDD. Table 2 reports details of this group of patients. 
In the ROC analysis, that allowed us to find the FXIII:C level that better discriminates 
patients with from those without grade III bleeding, the FXIII level of 15 IU/dL 
corresponded to a sensitivity of 97% (95% CI: 83 to 99%) and a specificity of 76% 
(95% CI: 58 to 90%). The AUC of the ROC curve sorting from the full logistic model 
was 0.96 (95% CI: 0.93 to 1.00) (Fig. 4). After correction for optimism (1000 
bootstrap replicates), the AUC became 0.94. In a full logistic model where FXIII:C 
was dichotomized at the cut-off point of 15 IU/dL, the AUC of the ROC curve was 
very similar (0.95 [95% CI: 0.91 to 0.99]). 
 
DISCUSSION 
FXIII deficiency is a rare disorder characterized by episodes of severe bleeding. 
Because of the low prevalence, studies have historically described individual case 
reports or small series of patients, limiting what could be learned from the reported 
findings. In our previous report on the EN-RBD study, we described a new method to 
classify bleeding severity and laboratory phenotype severity for the first time in a 
European group of patients [20].This classification made important steps towards 
standardization of the diagnosis and treatment of FXIII deficiency, but has not been 
validated in a real-life representative patient population. In this cross-sectional study, 
we have confirmed the usefulness of the EN-RBD FXIII deficiency classification 
system by analyzing the baseline data of 64 FXIII-deficient patients from the ongoing 
PRO-RBDD study. We found that FXIII plasmatic activity correlates well with two 
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important clinical parameters: age at first bleeding and age at diagnosis, considered 
two parameters of clinical severity of patients. Almost all patients with undetectable 
FXIII:C up to 29 IU/dL were diagnosed due to bleeding episodes, while patients with 
FXIII:C ≥30 IU/dL were diagnosed following an isolated non-major bleeding episode 
or as family member of an affected patient. 
Grade III bleeding was observed in 55% of all patients, similar to the value of 48.5% 
described in our previous study [20]. We consider this as a validation study of the 
previous EN-RBD data collection which assessed that patients with FXIII deficiency 
require a FXIII:C ≥ 30 IU/dL to remain asymptomatic [20]. However, the wide range 
of FXIII activity (from the lower detection limit to 29 IU/dL) associated with a highly 
variable bleeding tendency (from grade I to III), led us to identify a FXIII activity level 
to prevent spontaneous major bleeding. This decision was made aiming to support 
clinicians in their decision on which patients could benefit from prophylaxis and what  
FXIII:C level could be considered safe. Our results showed that the probability of 
grade III bleeding (as umbilical, gastrointestinal and central nervous system 
bleeding, hemarthrosis and hematoma) steeply increases when FXIII coagulant 
activity levels fall below 20 IU/dL. In particular, the FXIII cut-off level of 15 IU/dL 
corresponded to a sensitivity of 97%, thus identifying almost all patients with grade III 
bleeding (the only one that was not identified had FXIII coagulant activity level of 16 
IU/dL). We recognize that the limited number of patients does not allow for a definite 
clear cut-off for prophylaxis. However, since in this study the highest FXIII level 
associated with grade III bleeding was 16 IU/dL, and the probability of grade III 
bleeding increased from 50% to more than 90% for levels of 15 IU/dL or lower, a 
value of 15 IU/dL seems a reasonable level to be suggested for the initiation of 
prophylaxis. Interestingly, this result looks similar to the previous data obtained by 
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Kerlin et al evaluating pharmacokinetics of recombinant FXIII, which showed that the 
trough geometric mean FXIII activity level was 0.16 IU/mL (i.e.,16 IU/dl) [31]. 
Whether or not this FXIII cut-off should be maintained as trough level during 
prophylaxis cannot be answered by the present study, in which all the analyses were 
based on laboratory and clinical data collected at baseline. The trough level might be 
lower than 15 IU/dL, since during prophylaxis the period of exposure to very low 
levels of FXIII is shorter than that in the absence of prophylaxis, and limited to the 
period immediately before the next dose of FXIII concentrate. This shorter exposure 
period might be insufficient to trigger spontaneous major haemorrhages. Anyway, 
the answer to this question will only be possible in a prospective study on FXIII 
deficient patients receiving prophylaxis, where a correlation between trough FXIII 
levels and bleeding events (if any) can be made. 
Recent prospective studies have suggested that prophylactic treatment of FXIII 
deficiency with FXIII concentrate is safe and effective in patients at high risk of life-
threatening bleeding [22,24]. Additionally, FXIII has a long half-life, therefore it is 
administered only once every four to six weeks [13]. Despite this, only 61% of 
patients with severe FXIII deficiency in the PRO-RBDD database were on 
prophylactic FXIII treatment at enrolment, probably due to the lack of product in 
some countries.  
To our knowledge, no prospective studies with the purpose to collect data on any 
type of hemorrhagic event (spontaneous, post-trauma, post-surgery or other) and 
any type of possible treatment for FXIII deficiency is currently ongoing, except the 
Post Approval Safety Surveillance Mentor™ 6 by NovoNordisk. Analyses of the 
follow-up data recorded into the PRO-RBDD to determine whether prophylactic 
treatment could successfully reduce severe clinical bleeding episodes in this FXIII-
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deficient patient population are ongoing. It will be also useful to confirm the results of 
the current analysis (exclusively based on data at enrolment) because less subjected 
to the possible errors due to investigation of medical history, by its nature less 
accurate. The main limitation of our study is that clinical records predominantly 
included patients presenting with bleeding symptoms. With this selection bias, 
individuals from the general population, with moderate-to-severe FXIII deficiency and 
few (or no) bleeding symptoms, were less likely to have been included in this study. 
This could have led to ascertainment bias with an overestimation of the risk of 
bleeding according to FXIII activity levels. Only studies recruiting index cases and 
family members that are followed over time will yield more precise risk estimates. 
However, this limitation is unlikely to affect management strategies, as in a daily 
clinical practice physicians deal with patients referred because of bleeding symptoms 
(thus a selected group of individuals with FXIII deficiency), and within this group they 
should discriminate patients who may benefit from prophylaxis with FXIII 
concentrates to prevent grade III bleeding. Another limitation is that samples were 
centralized for a methodologically uniform FXIII measurement in only half of the 
patients. However, since the main purpose of this re-analysis was to improve the 
lower limit of FXIII detection, most of the samples re-tested were in the severe 
laboratory group (i.e., undetectable FXIII), and a very high correlation between the 
two values of the local and central laboratories was found, the possibility of having 
misclassified FXIII deficient patients is low. Hence, we are confident that a similar 
high correlation would also apply to the other samples tested only at the local 
laboratory. 
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In conclusion, we have presented an analysis of baseline data from an ongoing 
study of an international FXIII-deficient patient population. These data allowed us to 
validate the EN-RBD classification and have helped to indicate a FXIII activity cut-off 
of 15 IU/dL to prevent spontaneous major bleedings. The continuation of the study 
including a centralized FXIII testing extended to all patients and strict criteria 
regarding FXIII washout might confirm this minimal level as a target value to start 
prophylaxis in patients affected by congenital FXIII deficiency.  
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TABLE 
Table 1. Baseline characteristics of the 64 patients with FXIII deficiency. 
 
Sex  (Male/Female), N 31 / 33 
Median age (IQR), yrs 27 (16–40) 
Patients aged ≤12 years, N (%) 8 (13) 
 Severe 
(undetectable) 
Moderate 
(lower 
detection 
limit  to 29 
IU/dL) 
Mild  
(≥30 IU/dL) 
Laboratory severity*
,§, N (%) 31 (49)     13 (21) 19 (30) 
Bleeding severity*
,¶
  
Asymptomatic, N (%) 0 (-) 0 (-) 6 (43) 
Grade I, N (%) 2 (7) 5 (39) 3 (21) 
Grade II, N (%) 1 (3) 2 (15) 5 (36) 
Grade III, N (%) 28 (90) 6 (46) 0 (-) 
 
* Based on classification according to EN-RBD (Peyvandi et al). 
§ Information not available for one patient with grade III bleeding. 
¶ Five patients with mild deficiency were not classified because they had exclusively bleeding 
during pregnancy. 
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Table 2. Characteristics of the 6 patients with FXIII:C levels between 5 and 16 IU/dL and grade III bleeding. 
 
Patient 
Age at 
diagnosis 
Laboratory severity  
(method - date of measurement) 
Bleeding symptoms Country Mutation - genotype Prophylaxis 
1 23 months 
14 IU/dl  
(Photometric – local, at diagnosis) 
CNS 
Haematoma 
Mucocutaneous 
Umbilical cord 
Pakistan 
Ser414Leu  
homozygous 
NO 
2 24 months 
13 IU/dl  
(Photometric – local, after diagnosis) 
Mucocutaneous 
During pregnancy 
Spontaneous abortion 
Umbilical cord 
Pakistan 
IVS11+1 G>A-  
homozygous 
NO 16 IU/dl 
(Ammonia release - central, after 
diagnosis) 
3 3 months 
6 IU/dl 
(method NA - local, at diagnosis) 
CNS  
GI  
Haemarthrosis  
Haematoma  
Umbilical cord 
Germany 
Leu250SerfsX18  
homozygous 
NO 
4 14 years 
8 mg/L 
(ELISA A2B2 - local, at diagnosis) CNS 
Menorrhagia  
Mucocutaneous 
USA 
Arg 78Cys + Arg79Gly  
compound heterozygous 
YES 
Started one year after 
the diagnosis 
(45 U/Kg once/month) 
5 IU/dl 
(Amine incorporation – local , 21 days 
from the last prophylactic infusion) 
5 1 month 
5 IU/dl 
(Photometric - at diagnosis) 
Mucocutaneous 
Umbilical cord 
UK 
Phe9fs 
homozygous 
YES 
Started two months 
after the diagnosis 
(500 U once/3 weeks) 
6 1 year 
7 IU/dl 
(Amine incorporation - 30 days from 
the last prophylactic infusion 
29/01/2014) 
CNS  
Haemarthrosis  
Haematoma  
Mucocutaneous 
USA 
Arg704Trp + Arg172Stop 
compound heterozygous 
YES 
Started 13 years after 
the diagnosis 
(37 U/Kg once/month) 
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FIGURE LEGENDS 
Figure 1. Distribution of age at first bleeding (panel A) and age at diagnosis 
(panel B) according to laboratory severity of FXIII CD. The box plots represent 
the interquartile ranges, the solid horizontal line inside each box plot is the median 
value and the vertical bars delimit the min and max values of the distribution. The 
black circles identify single observation. 
 
Figure 2. A: Restricted cubic spline curve showing the age- and sex-adjusted 
relationship between FXIII activity levels and risk of grade III bleeding, 
expressed as log odds. The FXIII activity levels are truncated at the value of 30 
IU/dL, since patients with values above this point had no grade III bleeding.  
B: Probability curve showing the predicted probability of grade III bleeding 
according to FXIII activity levels. This curve is obtained following the relationship 
between log odds and probability (probability = exp(log odds) / [1 + exp(log odds)].  
The grey areas around the curves represent 95% CI.  
 
Figure 3. Distribution of FXIII activity levels according to presence or absence 
of grade III bleeding. The box plots represent the interquartile ranges, the solid 
horizontal line inside each box plot is the median value and the vertical bars delimit 
the min and max values of the distribution. The black circles identify single 
observation. 
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Figure 4. ROC curve showing the predictive ability of the full logistic model 
(containing FXIII:C levels, age and sex) for the discrimination of patients with 
or without grade III bleeding. The dashed diagonal line represents the situation of 
predictive uncertainty (AUC = 0.50). 
 
Appendix listing additional contributors of the PRO-RBDD study group: 
S. Halimeh,* B. Lachmann,* C. Bidlingmaier,† H. Platokouki,‡ H. Pergantou,‡ S. M. 
Siboni,§ R. E.G. Schutgens,¶  M. Borhany,** N. Fatima,** D. Mikovic,†† M. 
Saracevic,†† P. De Moerloose,‡‡ A. Casini,‡‡ N. Ozdemir,§§ Y. Ay,¶¶ A. 
Mumford,*** A. Harvey,*** J. Payne,††† A. D. Shapiro,‡‡‡ A. Williamson,‡‡‡ J. 
Chapin,§§§ F. Hsu,§§§ 
 
* Coagulation Center Rhine Ruhr, Duisburg, Germany;  
† Pediatric Hemophilia and Thrombosis Centre, Dr von Hauner’s Children’s 
University Hospital, Munich, Germany;  
‡ Haemophilia Centre/Haemostasis Unit, Agia Sofia Children’s Hospital, Athens, 
Greece;  
§ Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS 
Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy 
¶ Van Creveldkliniek, Universitair Medisch Centrum, Utrecht, Netherlands; 
** National Institute of Blood Disease & Bone Marrow Transplantation, Karachi, 
Pakistan;  
††Haemostasis Department, Blood Transfusion Institute of Serbia, Belgrade, Serbia;  
‡‡ Division of Angiology and Haemostasis, University Hospitals of Geneva, Geneva, 
Switzerland;  
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§§ Department of Pediatric Hematology, Cerrahpasa Medical Faculty of Istanbul 
University, Istanbul, Turkey;  
¶¶ Dr. Behcet Uz Children's Hospital, Izmir, Turkey;  
*** Bristol Haematology and Oncology Centre, Bristol, United Kingdom;  
††† Department of Haematology, Sheffield Childrens Hospital, Sheffield, United 
Kingdom;  
‡‡‡ Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA;  
§§§ Comprehensive Center for Hemophilia and Coagulation Disorders, Weill Cornell 
Medicine, New York Presbyterian Hospital, New York, NY, USA;  
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